Failure of Women’s Hearts
Mark C. Petrie, BSc, MRCP; Nuala F. Dawson, MRCP; David R. Murdoch, BMS, MRCP;
Andrew P. Davie, BSc, MRCP; John J.V. McMurray, MD, FRCP, FESC
R ecently, differences in the management of men and women with ischemic heart disease have been highlight- ed.1Although at least as great, sex differences in heart failure have received little attention. In this article, we review the evidence that men and women with heart failure may differ with respect to epidemiology, etiology, diagnosis, prognosis, and treatment.
Epidemiology
To date, most studies of the prevalence and incidence of heart failure have identified cases on clinical grounds and, in some instances, with the aid of an ECG and chest radiograph. Thus, the precise type of heart failure (eg, left ventricular systolic dysfunction, or valvular disease) is unclear in most reports.
This is important in view of the evidence that left ventricular systolic dysfunction is less common in women than in men with suspected heart failure (see the “Diagnosis” section below).
Prevalence
With these caveats in mind, the major epidemiological surveys of heart failure (see the Figure)
2–5show that the overall prevalence rate of heart failure is similar in men and women. This balance, however, reflects a much lower female prevalence
,70 to 75 years of age and a higher prevalence inolder women than in older men. Overall, within the popula- tion, there appear to be more women than men with heart failure.
6 – 8aAlthough age-adjusted rates for both sexes have decreased from 1988 –1995, rates for women have fallen less than those for men.
8bIncidence
Although the absolute incidence rate is lower than the prevalence rate, the effect of age on sex incidence is similar.
3Etiology
Risk factors for heart failure appear to differ markedly between the sexes.
Hypertension
The risk of heart failure imparted by hypertension is greater for women than for men. In the Framingham study, the hazard in a proportional hazards regression model (adjusting for age and other risk factors) for developing heart failure in
hypertensive compared with normotensive subjects is about doubled in men and tripled in women.
9In terms of population attributable risk, the effect of hypertension is greater in women (59%) than men (39%).
9These findings are supported by more recent studies such as the SOLVD trials in which in the treatment trial women were more likely to have concom- itant hypertension (55% of women versus 39% of men,
P,0.001).10The higher prevalence of hypertension in women when compared with men with heart failure is seen in both blacks (64.2% of women versus 60.2% of men; P
,0.05) andwhites (42.9% of women versus 35.7% of men; P
,0.05).8bThis difference between men and women may reflect a sex difference in the cardiac response to an increase in afterload.
11Coronary Artery Disease
The SOLVD trials
10reported that coronary heart disease and, in particular, past myocardial infarction are less frequently identified as an etiological factor in women than in men with heart failure (Table 1).
Furthermore, although white women admitted with heart failure have less coronary artery disease than their male counterparts, black women appear to have more coronary artery disease than black men.
8bAlthough the incidence of myocardial infarction is lower in women than in men, women who do sustain a myocardial infarction are more likely to develop heart failure.
12–14Inter- estingly, women are also more likely to develop heart failure after CABG than men (relative risk in CASS, 2.71; 95% CI, 1.86 to 3.93).
15Diabetes Mellitus
Diabetes seems to be a stronger risk factor for heart failure in women than in men, especially in younger women. Several studies,
16,17including SOLVD,
18have reported that women with heart failure are more likely to have diabetes than men (SOLVD,
1949.3% women and 37.2% men, P
,0.02). In theFramingham study, although both young women and young men with diabetes had a greater incidence of heart failure than those without, the effect was greater in women (an 8-fold versus a 4-fold increase).
3A distinct diabetic cardiomyopathy has been proposed, and in the Framingham study, increased wall thickness and left ventricular mass were found in women but not in men with diabetes mellitus.
20From the Medical Research Council Clinical Research Initiative in Heart Failure, Wolfson Building, University of Glasgow, and Department of Cardiology, Western Infirmary, Glasgow, Scotland.
Correspondence to Prof John J.V. McMurray, Medical Research Council Clinical Research Initiative in Heart Failure, Wolfson Building, University of Glasgow, Glasgow G11 6 NT, Scotland. E-mail J.McMurray@bio.gla.ac.uk
(Circulation. 1999;99:2334-2341.)
© 1999 American Heart Association, Inc.
2334
Downloaded from http://ahajournals.org by on November 14, 2021
Obesity, Cholesterol, and Smoking
Obesity (relative weight) is independently associated with congestive heart failure in women and men.
21The Framing- ham study identified a greater predictive value of obesity in women.
22The ratio of total to HDL cholesterol has also been identified as an independent risk factor for heart failure.
22Total cholesterol is significantly related to the incidence of heart failure only in men
,65 years of age. Smoking in thesame study was also found to increase the risk of heart failure in young men and old women.
22Smoking is less common in female than male heart failure patients.
14Valvular Heart Disease
The SOLVD,
23Framingham,
24and hospital-based
8bstudies report a predominance of women with valvular heart disease.
However, data from the 30-year follow-up of the Framing- ham study suggest a declining frequency of heart failure secondary to valvular disease in both sexes.
24Rheumatic heart disease declined from 22% to 15% in women and 15%
to 3% in men over this time period.
24Idiopathic Dilated Cardiomyopathy
Women are reported to have a markedly lower prevalence of idiopathic dilated cardiomyopathy in many studies (male-to- female ratio, 1.9 – 4.3:1),
8b,25–28perhaps because the male population has a greater prevalence of covert alcohol abuse or asymptomatic coronary artery disease. Women who do de- velop idiopathic dilated cardiomyopathy, however, have greater ventricular dimensions and shorter exercise dura- tion.
29It should be noted, however, that more women than men had an “unknown” cause of left ventricular systolic dysfunction in the SOLVD trials (16% versus 9% in men in the prevention arm and 26% versus 16% in the treatment arm,
P,0.001).10Alcoholic Cardiomyopathy
The evidence of a sex influence on susceptibility to alcohol- induced heart failure is inconclusive. Despite a mean lifetime alcohol dose of 60% of that of their male counterparts, women have been found to suffer from alcoholic cardiomy- opathy at a similar rate.
30Another study has found a positive association between alcoholic cardiomyopathy and male sex.
31Further studies are required to examine this issue.
Peripartum Cardiomyopathy
Peripartum cardiomyopathy is a rare but important disorder that has been reviewed elsewhere.
32X-Linked Cardiomyopathy
Families with patterns of inheritance suggesting an X-linked cardiomyopathy have been described.
33–37Clinical expression is that of early onset and rapid progression in men and later
Sex differences in prevalence of heart failure and left ventricular systolic dysfunction in major epidemiological studies. *Based on clini- cal criteria; **based on echocardiography.TABLE 1. Coronary Heart Disease as a Cause of Chronic Heart Failure in SOLVD
Proportion With Coronary Heart Disease, %
Proportion With Previous Myocardial
Infarction, %
Trial Men Women Men Women
SOLVD Treatment
74 61 69 56
SOLVD Prevention
84 74 82 69
Downloaded from http://ahajournals.org by on November 14, 2021
onset and slower progression in women. Work to further classify the genetic abnormalities concerned is continuing.
Diagnosis
The few small studies that have looked at the diagnosis of heart failure have reported a striking sex difference. This relates to the prevalence of left ventricular systolic dysfunc- tion in patients treated with diuretics for “heart failure” or presenting with symptoms and signs suggestive of new-onset heart failure. One Scottish study reported that 19 of 30 men (63%) being treated with diuretics alone had echocardio- graphic evidence of left ventricular dysfunction compared with 13 of 48 women (27%).
38Obesity and pulmonary diseases were frequently the underlying pathology. A second Scottish study found that only 12 of 66 women (18%) and 19 of 53 men (36%) being treated for heart failure by their general practitioners had echocardiographic evidence of left ventricular dysfunction.
39A Finnish study found that 21 of 37 men (57%) but only 7 of 51 women (14%) with suspected heart failure had definite heart failure as assessed by a clinical scoring system.
40In a recent study from London, Cowie et al
41reported that 41% of male but only 17% of female patients referred with suspected heart failure actually had this syn- drome. Data from another English study of 505 patients receiving diuretics from their general practitioners also sug- gest that diagnosis of heart failure in women is less accurate than in men.
42Although more women than men were found to be prescribed a loop diuretic, fewer women satisfied the authors’ criteria for a diagnosis of heart failure. The cause of symptoms and signs in the women without left ventricular systolic function was not clear in these reports. Whereas
“diastolic dysfunction” is possible, 2 of the above studies found that obesity was more prevalent in women,
38,40and in 1 study, diastolic dysfunction as measured by the mitral valve Doppler E/A ratio was uncommon.
43Patient Management Hospital Referral
Few studies have examined the possibility of a sex bias in referring patients with heart failure to hospitals. One study, however, has found that women with heart failure were less likely to be referred to hospital than men and were more likely to be treated by their general practitioners.
42Women with heart failure are less likely to be referred to a teaching hospital and, once admitted, are less likely to be managed by cardiologists than men.
8bPatient Investigation
There are few data in the literature on the use of investiga- tions according to sex. In 1 report, however, women were less likely than men to undergo measurement of left ventricular function (36% of women versus 42% of men).
44A further large study of patients admitted with heart failure found that women were equally likely to have an echocardiogram but were less likely to undergo cardiac catheterization. Both black and white women were less likely than men to undergo ventriculography, Holter monitoring, and exercise stress testing.
8bMorbidity
The major source of information on sex and morbidity is studies on hospital admissions and discharges for heart failure.
Quality of Life
The limited data available on quality of life in heart failure include an analysis by the SOLVD investigators that found that women experience greater shortness of breath on exer- tion (58% versus 48% of men, P
,0.001) and make up fewerof the NYHA class 1 subgroup (6% versus 12%, P
,0.001)than men.
10This trend toward greater functional impairment was seen in both the treatment and prevention trials. In a series of 45 894 patients admitted with heart failure, women had lower baseline physical health status and experienced less improvement in the year after admission than men.
44aIn contrast to these two large studies, several small studies have failed to show differences in quality of life.
44b– 44dWomen with idiopathic dilated cardiomyopathy have been found to have a shorter exercise duration.
29Although far from exhaustive, this evidence suggests that women with heart failure have a poorer quality of life.
Symptoms and Signs
Women appear to experience more symptoms and present more frequently with signs of heart failure. The SOLVD investigators found that women had more edema than men (15% of men versus 22% of women).
10More women than men had an audible third heart sound (17% versus 11%,
P,0.001) and elevated jugular venous pressure (17% versus5%, P
,0.001).10Women with idiopathic dilated cardiomy- opathy report more symptoms and a shorter exercise duration and present more frequently with heart failure signs.
29Again, the data are limited but are consistent with the findings on quality of life reported earlier.
Hospitalizations for Heart Failure
In keeping with the population prevalence of heart failure, published reports of hospitalization from the United King- dom,
8Sweden,
31New Zealand,
45the United States,
6,7,16,46and the Netherlands
47all show higher hospital admission and discharge rates for men than women in younger age groups with a diminishing difference in older age categories. Be- cause the highest prevalence rate is found in older subjects and because there are more older women than men in most first-world populations, the absolute number of hospitaliza- tions for women is greater than that for men.
7,8Women in the SOLVD Registry had a higher annual admission rate than men (22% versus 17%, P
50.05).48Women also have consistently longer stays in the hospital than men.
8,8b,45,47The reason for this is not clear. Women with congestive heart failure are older,
47– 49and age influences length of stay.
45,47Women may also have more comorbidity and be more likely to live alone. Readmission rates, however, were independent of sex in 2 studies
8,50and lower for women in another.
51Thromboembolism
Left ventricular ejection fraction is inversely associated with the risk of thromboembolism in women but not in men.
52Downloaded from http://ahajournals.org by on November 14, 2021
Women with heart failure are also at greater risk of pulmo- nary embolism than men (P
50.01).52It is not clear whether or not the sex difference in morbidity in the above studies reflects later referral, more advanced ventricular dysfunction, or a biological difference between the sexes (or some combination of these factors).
Mortality
The 2 largest US epidemiological studies, Framingham
49and the first NHANES-1,
2both reported a better survival in women with heart failure. Median survival was 3.2 years for women versus 1.7 for men in the Framingham study. The 5-year survival rate was 38% for women compared with 25%
for men. This survival benefit was apparent despite the greater average age of women (72 years) compared with men (68 years). Adjusting for age and origin of heart failure exaggerated this difference in prognosis. NHANES-1 also reported a better outlook for women than men over a 10- to 15-year period of follow-up, and this was seen across all age groups.
2Other population surveys
6,53and studies of patients admitted to hospital
8b,50also report a more favorable progno- sis in women.
In contrast, the SOLVD investigators reported quite the opposite finding; they described a worse outlook for women who had a 1- year mortality rate of 22% compared with 17%
for men (P
50.05).48This survival differential was apparent for total mortality, cardiac mortality, death from progressive pump failure, and presumed arrhythmic death.
These contrasting findings are interesting and important.
As alluded to earlier, fewer women with the symptoms and signs of heart failure have left ventricular systolic dysfunc- tion, ie, the form of heart failure with the gravest prognosis.
Interestingly, even in the CONSENSUS-1 study, in which patients were not recruited on the basis of left ventricular function, women were much more likely to have echocardio- graphic fractional shortening above the median than men (48% of women versus 15% of men, P
,0.05).54Framing- ham
49and NHANES-1
2did not assess left ventricular func- tion, whereas all patients in SOLVD
48had reduced left ventricular ejection fractions. SOLVD, therefore, represents a more homogeneous group of patients with a particular type of heart failure. Etiology may also explain in part the differences between SOLVD and Framingham and NHANES-1. As with men, women with heart failure that is not caused by coronary heart disease fare better than those with coronary heart failure. SOVLD contained more women with coronary heart failure than Framingham or NHANES-1. Whatever the ex- planation, the worse prognosis of women in SOLVD is unsurprising given their greater symptom burden and poorer quality of life (see above). Women in the SOLVD trials also had more cardiomegaly (cardiothoracic ratio
.0.5) than men:51% versus 37% in men in the prevention arm (P
,0.001) and65% versus 53% in the treatment arm (P
,0.001).10Once again, it is unclear whether these sex differences reflect later referral, more advanced disease, or a biological difference between the sexes.
Women in Clinical Trials in Heart Failure
Women have been hugely underrepresented in heart failure trials and trials of left ventricular dysfunction. The proportion
of randomized patients in the major trials ranges from 0% to 32%, yet there are probably more women than men with heart failure in the population (Table 2). This almost certainly does not represent differences in the willingness of women and men to participate in trials. In the SOLVD closeout question- naire, women more frequently reported participating to at- tempt to liver longer, whereas men were more likely to want to contribute to medical science.
55Trials of Digoxin, b-Blockers, and Hydralazine Plus Isosorbide Dinitrate
Trials of digoxin in heart failure have not reported subgroup analyses by sex.
66 – 68Although reporting a total of only 14 deaths in women, the US Carvedilol Group found a statisti- cally significant reduction in the number of deaths in women and men.
65The other large
b-blocker trials have not reportedsex-specific mortality.
66 – 68The V-HeFT Trial, which showed a mortality benefit with the vasodilating combination of isosorbide dinitrate and hydralazine, recruited only men.
56Trials With ACE Inhibitors in Heart Failure ACE inhibitors are widely used in the management of heart failure in both men and women. The large multicenter trials that have reported mortality and morbidity benefit, however, have contained only a small proportion of women. Subgroup analysis of the CONSENSUS-1 study showed a statistically significant reduction in mortality with enalapril in men but not in women.
69Whereas men achieved a 51% reduction in 6-month mortality (P
,0.001), women achieved only a 6%reduction (P
5NS). The SOLVD investigators found that menand women treated with enalapril experienced a reduction in mortality and hospitalizations, although this effect was less for women.
1These trials, however, contained small numbers of women and were not designed to examine mortality benefit in women and men separately. In a meta-analysis of the ACE inhibitor trials, the survival benefit with active therapy appeared to be similar in both sexes: 0.76 for men and 0.79 for women.
70Active therapy had a similar effect on the combined end point of total mortality and hospitalizations:
TABLE 2. Women in Large Heart Failure Trials
STUDY
No. of
Women % Women
V-HeFT-I56 0 0
V-HeFT-II57 0 0
CONSENSUS-158 75 30
SOLVD-T59 504 19.5
SOLVD-P60 482 11
ELITE61 20 32
MDC62 10 27.5
CIBIS63 112 17.5
Aus/NZ-HFRCG64 82 20
US Carvedilol Group65 256 23.5
DIG66 1520 22.5
PROVED67 88 15
RADIANCE68 178 24
Downloaded from http://ahajournals.org by on November 14, 2021
0.63 for men and 0.78 for women. However, the odds ratios (ACE inhibitor versus placebo) for women, unlike those for men, crossed 1.00 for the end point of total mortality and the combined end point of total mortality and hospitalization for heart failure.
Trials With ACE Inhibitors in Patients With Post–Myocardial Infarction Left Ventricular Systolic Dysfunction and Heart Failure
In the AIRE study, treatment with ramipril in patients with signs of heart failure after myocardial infarction led to a significant reduction in mortality in both sexes.
71The other 3 studies of ACE inhibitors in patients with left ventricular dysfunction after myocardial infarction did not report a significant mortality benefit for women. TRACE included 28% women, and the relative risks with trandolapril were 0.75 (95% CI, 0.62 to 0.89) for men and 0.90 (95% CI, 0.69 to 1.18) for women.
72In the SMILE trial, the relative risks with zofenopril were 0.59 (95% CI, 0.36 to 0.95) for men and 0.70 (95% CI, 0.40 to 1.21) for women.
73In SAVE, the results for women were again disappointing.
74There was only a 2% mortality risk reduction in women versus a 22% risk reduction in men. For the combined end point of cardiovas- cular death and morbidity, there was only a 4% risk reduction in women but a 28% risk reduction in men. After adjustment for other variables (such as age), however, the relative risks of an end point for women and men were 19% and 21% in the ACE inhibitor group.
Although these results with ACE inhibitors in heart failure and after myocardial infarction reflect, at least in part, the small numbers of women included in the trials, they do leave open the possibility that ACE inhibitors are less effective in women. This, in turn, could reflect a higher rate of treatment withdrawal in women (see the “Adverse Effects” section).
Angiotensin II Receptor Antagonists
The ELITE study recently compared the effects of the angiotensin II type 1 receptor antagonist losartan and the ACE inhibitor captopril, suggesting that the former treatment may be more effective.
61Again, the numbers of women were small (ratio of men to women: losartan, 234:118; captopril, 248:122). The distribution of deaths in women (9 of 118 and 8 of 122 deaths in the losartan and captopril groups, respec- tively) does not support the extrapolation of any trend in mortality benefit to women.
Sex Differences in the Adverse Effect Rate in ACE Inhibitor Trials
There was a higher rate of adverse effects reported by women than by men in the SOLVD trials. This sex difference was seen during both the medication challenge phase of SOLVD
75and long-term treatment.
76The sex difference in coughing is perhaps best recognized and may reflect the greater average milligram-per-kilogram dose of drug received by women in trials using a fixed absolute-dosing regimen. Women, how- ever, are also more likely to experience other side effects, including a greater rise in creatinine, taste disturbance, skin rash, and gastrointestinal upset.
Other Sex Influences on Response to Pharmacological Treatment
Female sex is a risk factor for torsade de pointes with
D
-sotalol, an agent shown to increase mortality in patients with left ventricular systolic dysfunction.
77Underprescription of ACE Inhibitors in Women With Heart Failure and Left
Ventricular Dysfunction
Women receive ACE inhibitors less often than men as treatment for heart failure,
78,79even in the absence of contra- indications.
80The cause of ACE inhibitor underprescription for both sexes, and particularly the sex disparity, is unclear.
Oversight and ignorance of prognostic benefit would seem likely candidates for suboptimal use in both sexes. Perhaps physicians recognize women to be at greater risk of adverse effects than men, although this should not necessarily pre- clude treatment.
Adherence to Prescribed Therapy
In 1 study, women were significantly more adherent to prescribed digoxin treatment than men.
81Heart Transplantation
Women constitute only 20% of patients undergoing trans- plantation.
82The reasons for this striking sex discrepancy are unclear. Premature coronary heart disease in men and a male preponderance of idiopathic dilated cardiomyopathy may lead to more men in a younger age group with heart failure of greater severity than women. It has also been reported that women are more likely to decline transplantation.
83Women have an increased frequency of allograft rejection and are less likely to tolerate a steroid-free regimen after transplantation.
84It is not clear whether women and men have comparable survival after transplantation.
85,86Is There a Pathophysiological Basis for the Sex Differences in Heart Failure?
Although many of the sex differences in heart failure high- lighted in this review may be explained by differences in referral and treatment patterns, there is also evidence that some of these differences could have a pathophysiological basis. The myocardial response to injury may vary between sexes.
Sex differences in left ventricular responses to hyperten- sion
11and aortic stenosis
87– 89have been found. Premeno- pausal women with mild hypertension have smaller ventric- ular dimensions and enhanced ventricular performance compared with men.
11Olivetti et al
90found that aging female hearts do not suffer from the annual 1-g myocyte loss seen in male hearts. Data from SOLVD found male but not female sex to be a predictor of left ventricular dilatation (P
,0.04).91Women admitted with heart failure have less frequent serious ventricular arrhythmias than men.
8bInvestigation of possible sex differences in the neuroendo- crine response to heart failure is awaited. Variation in vascular responsiveness according to sex has not been de- scribed in heart failure.
Downloaded from http://ahajournals.org by on November 14, 2021
Any pathophysiological basis of sex differences in heart failure is likely to reflect a complex interaction of hormonal, vascular, and ventricular factors.
Conclusions
Heart failure in women differs in many aspects from that of men. Contrasts in origin, diagnostic yield, prognosis, and possibly response to treatment have been outlined. Some of these differences may have a pathophysiological basis. These sex differences may have widespread implications in the field of heart failure. Elucidation of a pathophysiological basis of sex differences, together with clinical trials designed to study the impact of treatments in women, could lead to some aspects of heart failure management being sex based. Until now, women have been profoundly underrepresented in clinical trials, and little investigation of sex influence on pathophysiology has been carried out. The large and consis- tent difference in the yield of left ventricular systolic dys- function in women versus men with suspected heart failure is puzzling and requires explanation. What is wrong with these female patients? It is hoped that the coming decade will see increased interest in this important area and, ultimately, a benefit for female heart failure sufferers.
Acknowledgment
Dr Petrie is funded by a British Heart Foundation junior research fellowship (No. FS/97031:1997).
References
1. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1992;329:247–256.
2. Schocken DD, Arriata MI, Laever PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol.
1992;20:301–306.
3. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993;22:6A–13A.
4. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall Pedoe H, McMurray JJV, Dargie HJ. Symptomatic and asymptomatic left ventric- ular systolic dysfunction. Lancet. 1997;350:829 – 833.
5. Mosterd A. Epidemiology of Heart Failure. Rotterdam: Erasmus Univer- sity;1997:77– 85. Thesis.
6. Gillum RF. Heart failure in the United States 1970 –1985. Am Heart J.
1987;113:1043–1045.
7. Ghali JK, Cooper R, Ford E. Trends in rates for heart failure in the United States 1973–1986: evidence for increasing population prevalence. Arch Intern Med. 1990;150:769 –773.
8. McMurray JJV, McDonagh TA, Morrison CE, Dargie HJ. Trends in hospitalisation for heart failure in Scotland. Eur Heart J. 1993;14:
1158 –1162.
8a.Haldeman GA, Rashidee A, Horswell R. Changes in mortality from heart failure—United States, 1980 –1995. JAMA. 1998;280:874 – 875.
8b.Philbin EF, DiSalvo TG. Influence of race and gender on care process, resource use, and outcomes in congestive heart failure. Am J Cardiol.
1998;82:76 – 81.
9. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to heart failure. J Am Coll Cardiol. 1996;275:
1557–1562.
10. Johnstone D, Limacher M, Rousseau M, Liang CS, Ekelund L, Herman M, Stewart D, Guillotte M, Bjerken G, Gaasch W, Held P, Verter J, Stewart D, Yusuf S. Clinical characteristics of patients in the Studies of Left Ventricular Dysfunction. Am J Cardiol. 1992;70:894 –900.
11. Garavaglia GE, Messerli FH, Schmieder RE, Nunuez BD, Oren S. Sex differences in cardiac adaptation to essential hypertension. Eur Heart J.
1989;10:1110 –1114.
12. Tofler GH, Stone PH, Mueller JE, Willich SN, Davis VG, Poole WK, Srauss HW, Willerson JT, Jaffe AS, Robertson T, Passamani E, Braunwald E. Effects of gender and race on prognosis after myocardial
infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol. 1987;9:473– 482.
13. Kimmelstiel C, Goldberg RJ. Congestive heart failure in women: focus on heart failure due to coronary artery disease and diabetes. Cardiology.
1990;77(suppl 2):71–79.
14. Kannel WB. Epidemiological aspects of heart failure. Cardiol Clin. 1989;
7:1–9.
15. Hoffman RM, Psaty BM, Kronmal RA. Modifiable risk factors for incident heart failure in the Coronary Artery Surgery Study. Arch Intern Med. 1994;154:417– 423.
16. Croft JB, Giles WH, Pollard RA, Casper ML, Anda RF, Livengood JR.
National trends in the initial hospitalization for heart failure. Am J Public Health. 1997;87:643– 648.
17. Krumholz HM, Parnt EM Tu N, Vaccarino V, Wang Y, Radford MJ, Hennen J. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99 –104.
18. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC. Diabetes mellitus: a predictor of mor- bidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77:1017–1020.
19. Limacher MC, Johnstone DE, Rousseau MF, Liang CS, Stewart DK, Stewart D, Yusuf S. Differences between men and women with left ventricular dysfunction. Circulation. 1991;83(suppl I):I-733. Abstract.
20. Galderisi M, Andersson KM, Wilson PWF, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85– 89.
21. Hubert HB, Feinleib M, McNamara P, Castelli WP. Obesity as an inde- pendent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham study. Circulation. 1983;67:968 –977.
22. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J.
1991;121:951–957.
23. Bangdiwala SI Weiner DH, Bourassa ML, Freisinger GC, Ghali JK, Yusuf S, for the Studies of Left Ventricular Dysfunction Investigators.
SOLVD Registry: rationale, design, methods and description of baseline characteristics. Am J Cardiol. 1992;70:347–353.
24. Kannel WB, Pinsky J. Trends in cardiac failure: incidence and causes over three decades in the Framingham Study. J Am Coll Cardiol. 1991;
17(suppl 2):87A. Abstract.
25. Williams DG, Olsen EGJ. Prevalence of dilated cardiomyopathy in two regions of England. Br Heart J. 1985;54:153–155.
26. Codd MB, Sugrue DD, Gersh BJ, Melton J. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. Circulation. 1989;80:564 –572.
27. Bagger JP, Bandruup U, Rasmussen K, Moeller M, Vesterlund T. Car- diomyopathy in western Denmark. Br Heart J. 1984;52:327–331.
28. Torp A. Incidence of congestive cardiomyopathy. Postgrad Med J. 1978;
54:435– 437.
29. De Maria R, Gavazzi A, Recalcati F, Baroldi G, DeVita C, Camerini F, for the Italian Multicentre Cardiomyopathy Study Group (SPIC). Com- parison of the clinical findings in idiopathic dilated cardiomyopathy in women versus men. Am J Cardiol. 1993;72:580 –585.
30. Urbano-Marquez A, Estruch R, Fernandeez-Sola J, Nicolas M, Pare JC, Rubin E. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA. 1995;274:149 –154.
31. Andersson B, Waagstein F. Spectrum and outcome of congestive heart failure in a hospitalized population. Am Heart J. 1993;126:632– 640.
32. Lee W, Cotton DB. Peripartum cardiomyopathy: current concepts and clinical management. Clin Obstet Gynecol. 1989;32:54 – 67.
33. Berko BA, Swift M. X-linked dilated cardiomyopathy. N Engl J Med.
1987;316:1186 –1191.
34. Evans W. Familial cardiomegaly. Br Heart J. 1949;11:68 – 82.
35. Biorck G, Orinius E. Familial cardiomyopathies. Acta Med Scand. 1964;
176:407– 424.
36. Csanady M, Szasz K. Familial cardiomyopathy. Cardiology. 1976;61:
122–130.
37. Ross RS, Bulkely BH, Hutchins GM. Idiopathic familial myocardiopathy in three generations: a clinical and pathological study. Am Heart J.
1978;96:170 –179.
38. Wheeldon NM, MacDonald TM, Flucker CJ, McKendrick AD, McDevitt DG, Struthers AD. Echocardiography in chronic heart failure in the community. Q J Med. 1993;86:17–22.
39. Francis CM, Caruana L, Kearney P, Love MP, Sutherland GR, Starkey IR, Shaw TRD, McMurray JJV. Open access echocardiography in man- agement of heart failure in the community. BMJ. 1995;310:634 – 636.
Downloaded from http://ahajournals.org by on November 14, 2021
40. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 1991;12:
315–321.
41. Cowie MR, Struthers AD, Wood DA, Coates AJS, Thompson SG, Poole Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;
350:1347–1351.
42. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J. 1994;71:584 –587.
43. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJV. The prevalence of left ventricular diastolic filling abnormalities in patients with suspected heart failure. Eur Heart J. 1997;18:981–984.
44. Sueta CA, Metts A, Griggs TR, Borders VC, Simpson RJ. ACE-I use and LV function in the elderly admitted with heart failure: gender differences.
J Am Coll Cardiol. 1997;29(suppl 2):17136. Abstract.
44a.Chin MH, Goldman L. Gender differences in 1-year survival and quality of life among patients with congestive heart failure. Med Care. 1998;36:
1033–1046.
44b.Dracup K, Walsen JA, Stevenson LW, Brect ML. Quality of life in patients with advanced heart failure. J. Heart Lung Transplant. 1992;11:
273–279.
44c.Romm RJ, Hulka BS, Mayo F. Correlates of outcomes in patients with congestive heart failure. Med Care. 1976;14:765–776.
44d.Burns RB, McCarthy EP, Moskowitz MA, Ash A, Kane RL, Finch M.
Outcomes for older men and women with congestive heart failure. J Am Geriatr Soc. 1997;45:276 –280.
45. Doughty R, Yee T, Sharpe N. Hospital admissions and deaths due to congestive heart failure in New Zealand. N Z Med J. 1995;108:474 – 475.
46. Graves EJ. Detailed Diagnosis and Procedures: National Hospital Dis- charge Survey 1989. Hyatsville, Md: National Center for Health Sta- tistics; 1991. DHHS publication (NHS) 91–1769, Vital Health Statistics Series 13, No. 108.
47. Reitsma JB, Mosterd A, De Craen AJM, Koster RW, Vanacapelle FGL, Grobee DE, Tijssen JGP. Increase in hospital admission rates for heart failure in the Netherlands 1980 –1993. Heart. 1996;76:388 –392.
48. Bourassa MG, Gurne O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S. Natural history and current practices in heart failure. J Am Coll Cardiol. 1993;22(suppl):14A–19A.
49. Ho KKL, Anderson KM, Kannel WB, Groossman W, Levy D. Survival after the onset of congestive cardiac failure in the Framingham Heart Study. Circulation. 1993;88:107–115.
50. Burns RB, McCarthy EP, Moskowitz MA, Ash A. Outcomes for older men and women with congestive heart failure. J Am Geriatr Soc. 1997;
45:276 –278.
51. Krumholz HM, Parnt EM, Tu N, Vaccarino V, Wang Y, Radford MJ, Hennen J. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99 –104.
52. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol. 1997;29:
1074 –1080.
53. Adams KF, Dunlap SH, Sueta CA, Clarke SW, Patterson JH, Blauwet MB, Jensen LR, Tomasko L, Koch G. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol. 1996;28:1781–1788.
54. Eriksson SV, Kjekshus J, Offstad J, Swedberg K. Patient characteristics in cases of chronic severe heart failure with different degrees of left ventricular systolic dysfunction. Cardiology. 1994;85:137–144.
55. Henzlova MJ, Blackburn GH, Bradley EJ, Rogers WJ, for the SOLVD Close-Out Working Group. Patient perception of a long-term clinical trial: experience using a close-out questionnaire in the Studies of Left Ventricular Dysfunction. Control Clin Trials. 1994;15:284 –293.
56. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B.
Effect of vasodilator therapy on mortality in congestive heart failure.
N Engl J Med. 1986;314:1547–1552.
57. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith RT, Dunkman WB, Loeb H, Wong ML, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Hakkenson C.
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med. 1991;325:303–310.
58. The CONSENSUS Trial Group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429 –1435.
59. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
N Engl J Med. 1991;325:293–302.
60. The SOLVD Investigators. Effect of enalapril on mortality and the devel- opment of heart failure in asymptomatic patients with reduced left ven- tricular ejection fractions. N Engl J Med. 1992;327:685– 691.
61. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, for the ELITE investi- gators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study). Lancet.
1997;349:747–752.
62. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;
342:1441–1446.
63. CIBIS Investigators, and Committees. A randomized trial of beta blockade in heart failure. Circulation. 1994;90:1765–1773.
64. Australia/New Zealand Heart Failure Research Collaborative Group.
Randomised, placebo-controlled trial of carvedilol in patients with con- gestive heart failure due to ischaemic heart disease. Lancet. 1997;349:
375–380.
65. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349 –1355.
66. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:
525–533.
67. The PROVED Investigative Group. Randomized study affecting the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol.
1993;22:955–962.
68. The RADIANCE study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting enzyme inhibi- tors. N Engl J Med. 1993;329:1–7.
69. Kimmelsteil C, Goldberg RJ. Congestive heart failure in women: focus on heart failure due to coronary artery disease and diabetes. Cardiology.
1990;77(suppl):71–79.
70. Garg R, Yusuf S, for the Collaborative Group on ACE inhibitor Trials.
Overview of randomized trials of angiotensin converting enzyme inhib- itors on mortality and morbidity in heart failure. JAMA. 1995;273:
1450 –1456.
71. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
Effect of ramipril on mortality and morbidity on survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet.
1993;342:821– 828.
72. The Trandolapril Cardiac Evaluation (TRACE) Group. A clinical trial of the angiotensin converting enzyme trandolapril in patients with left ven- tricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:
1670 –1676.
73. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80 – 85.
74. The SAVE investigators. Effect of mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement (SAVE) trial. N Engl J Med.
1992;327:669 – 677.
75. Kostis JB, Shelton B, Yusuf S, Weiss MB, Capone RJ. Tolerability of enalapril initiation by patients with left ventricular systolic dysfunction:
results of the medication challenge phase of SOLVD. Am Heart J.
1994;128:358 –364.
76. The SOLVD investigators. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction. Am Heart J. 1996;131:350 –355.
77. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex dif- ference in risk of torsades de pointes with D, L-sotalol. Circulation.
1996;94:2535–2541.
78. Clinical Quality Improvement Network. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure: the relative importance of age, sex and medical therapy. Arch Intern Med.
1996;156:1669 –1673.
79. Hillis GS, Trent RJ, Winton P, MacLeod AM, Jennings KP. Angiotensin converting enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence? Q J Med. 1995;89:145–152.
80. Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health. 1997;87:
643– 648.
Downloaded from http://ahajournals.org by on November 14, 2021
81. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med.
1994;154:433– 437.
82. Kaye MP. The Registry of the International Society for Heart and Lung Trans- plantation: 10thofficial report. J Heart Lung Transplant. 1994;13:561–570.
83. Aaronson KD, Schwartz JS, Goin JE, Mancini A. Sex differences in patient acceptance of cardiac transplantation candidacy. Circulation.
1995;91:2753–2761.
84. Crandall BG, Renland DG, O’Connell JB, Burton NA, Jones KW, Gay WA, Doty DB, Karwande SV, Lee HR, Holland C, Menlove RL, Hammond E, Bristow MR. Increased frequency of cardiac allograft rejection in female heart transplant recipients. J Heart Lung Transplant.
1988;7:419 – 423.
85. Weschler ME, Giardina EV, Sciacca RR, Rose AE, Barr ML. Increased early mortality in women undergoing cardiac transplantation. Circulation.
1995;9:1029 –1035.
86. Esmore D, Keogh A, Spratt P, Jones B, Chang V. Heart transplantation in females. J Heart Lung Transplant. 1991;10:335–341.
87. Carroll JD, Carroll EP, Feldman T, Ward DM, Lang RM, McGauchey D, Karp RB. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation. 1992;86:1099 –1107.
88. Aurigemma GP, Silver KH, McLaughlin M, Orsinelli D, Sweeney AM, Gaasch WH. Gender influences the pattern of left ventricular hypertrophy in elderly patients with aortic stenosis. Circulation. 1992;86(suppl II):
II-538. Abstract.
89. Douglas PS, Otto CM, Mickel MC, Labovitz A, Reid CL, Davis KB.
Gender differences in left geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis: NHLBI Balloon Valvuloplasty Registry. Br Heart J. 1995;73:548 –554.
90. Olivetti G, Giordano G, Corradi D, Melissari M, Lagrasta C, Gambert SR, Anversa P. Gender differences and aging: effects on the human heart.
J Am Coll Cardiol. 1995;26:1068 –1079.
91. Udelson JE, Kronenberg MW, Rousseau MF, Stewart D, Poulear H, Edeno TR, Kilcoyne L, Kinan D, Ahn S, Konstan MA. Determinants of progressive left ventricular dilatation in patients with left ventricular dysfunction. Circulation. 1992;86(suppl I):I-251. Abstract.
KEYWORDS: women
n
heart failuren
sexn
epidemiologyn
prognosisDownloaded from http://ahajournals.org by on November 14, 2021
![Crystal structure and Hirshfeld surface analysis of (E) 1 (4 chlorophenyl) 2 [2,2 dichloro 1 (4 fluorophenyl)ethenyl]diazene](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==)